Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.55 |
| ▸ | PTPRF | P10586 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.54 |
| ▸ | PRKCB | P05771 | 2/20 | 0.54 |
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | PRKCG | P05129 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | PRKACG | P22612 | 1/20 | 0.54 |
| ▸ | PRKACB | P22694 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548076 | 0.79 | PTPRC (0.54) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL7951074 | 0.78 | PTPN1 (0.73) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL5879323 | 0.73 | PTPRC (0.58) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL2193383 | 0.72 | PRKCB (0.65) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL1158441 | 0.72 | PTPRC (0.60) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL29771997 | 0.72 | PRKCB (0.65) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL8978222 | 0.72 | SIRT2 (0.51) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL1202543 | 0.72 | IMPDH2 (0.63) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL8992461 | 0.71 | PTPN1 (1.00) | PTPRCPTPRFPTPN1CDC25BSIRT2 | |
| SCHEMBL9572016 | 0.71 | PTPN1 (0.77) | PTPRCPTPRFPTPN1CDC25BSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094365-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | SNAP BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | SNAP BIO, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114222747-A | PIM kinase inhibitor composition and application thereof | 斯奈普生物公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112739345-A | PIM kinase inhibitor compositions, methods and uses thereof | 斯奈普生物公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020223306-A1 | PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF | SNAP BIO, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200331914-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | SNAP BIO, INC. | 2020-10-22 | — | — | US | disclosed |
| EP-3706735-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | Snap Bio, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| WO-2004083202-A1 | A PROCESS FOR THE PREPARATION OF INDOLYMALEIMIDES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
| EP-0888339-A4 | SYNTHESIS OF INDOLYLMALEIMIDES | LILLY CO ELI (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6037475-A | REACTING OPTIONALLY SUBSTITUTED, N-PROTECTED INDOL-3-YL-ACETAMIDE WITH AN ALKYL OXALATE AND A STRONG ORGANIC BASE IN A POLAR APROTIC SOLVENT FORMING OPTIONALLY SUBSTITUTED 4-(INDOL-3-YL)-3-HYDROXY PYRROLE-2,5-DIONE | ELI LILLY & COMPANY (US) | 2000-03-14 | — | — | US | disclosed |
| US-5919946-A | REACTING AN ACTIVATED MALEIMIDE WITH AN ORGANOMETALLIC-3-INDOLE IN PRESENCE OF A PALLADIUM TRANSITION METAL CATALYST | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5859261-A | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0888339-A1 | SYNTHESIS OF INDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034890-A1 | SYNTHESIS OF INDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094365-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | PIM1, PIM3, PIM2 | PTPRC 462/4885PTPRF 639/4885PTPN1 971/4885 |
| US-20200331914-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | PIM1, PIM2, PIM3 | PTPRC 516/4885PTPRF 592/4885PTPN1 1025/4885 |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | PIM1, PIM2, PIM3 | PTPRC 516/4885PTPRF 592/4885PTPN1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.